Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coli surface antigen 3 (CS3) is a major fimbrial adhesin (specifically a thin, flexible, wiry fibrilla) expressed on the surface of enterotoxigenic Escherichia coli (ETEC). It is a key component of the colonization factor antigen II (CFA/II) complex and plays a critical role in mediating bacterial adherence to host intestinal epithelial cells, which is the initial and essential step for ETEC colonization and subsequent diarrheal disease. CS3 is composed of the major structural subunit CstH (also known as CS3 fimbrial subunit A) and is assembled via a chaperone-usher pathway. Due to its high prevalence in clinical ETEC isolates associated with moderate-to-severe diarrhea in children in developing countries and in travelers, CS3 is a primary target for vaccine development. Several vaccine candidates, including the oral inactivated vaccine ETVAX and the live attenuated vaccine ACE527, incorporate CS3 to elicit protective mucosal IgA and systemic IgG antibody responses that block bacterial colonization. Additionally, CS3 has been identified as a host receptor for specific bacteriophages (such as IMM-002), highlighting its potential as a target for phage therapy.
Active immunization to elicit mucosal IgA and systemic IgG antibodies that bind to CS3, thereby blocking bacterial attachment to host intestinal epithelial cells and preventing colonization. Additionally, it serves as a receptor for specific bacteriophages (e.g., IMM-002) to mediate phage infection and lysis of enterotoxigenic Escherichia coli (ETEC).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coli surface antigen 3 (CS3).